Jing Bai;Yan Wang;
Objective: To analyze the clinical efficacies and treatment of patients with heart failure due to valvular and non-valvular heart disease by the use of recombinant human brain natriuretic peptide. Methods: 80 patients with valvular and non-valvular heart disease treated in our hospital are selected as the research objects from January 2018 to December 2018, and are divided into two groups according to the different types of the disease, namely, group A(n=40 cases) caused by valvular heart disease, and group B(n=40 cases) caused by non-valvular heart disease. Patients in both group A and B are treated with recombinant human brain natriuretic peptide, and the therapeutic effect and the level of each index are compared between the two groups. Results: There is no significant difference in the therapeutic effect between group A and group B. In the two indexes of CRP and BNP, group A is higher than group B(p<0.05). Conclusion: Patients with valvular and non-valvular heart disease have achieved good therapeutic effects with recombinant human brain natriuretic peptide, and patients with non-valvular heart disease have better therapeutic effects.
Valvular;;Non-valvular;;Heart disease;;Heart failure;;Recombinant human brain natriuretic peptide
To explore the background and basis of the node document
Documents that have the similar content to the node document